Premaitha: changing the landscape of non-invasive prenatal screening?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Premaitha: changing the landscape of non-invasive prenatal screening?
Released on: January 07, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Premaitha Health is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications.
  • Summary
  • Transcript
  • Participants
  • Company
Premaitha Health is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications.
Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. With a higher detection rate and lower false positive rate than existing screening tests it gives pregnant women, their families and their doctors greater confidence in the result and reduces the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities.
Steve Little, CEO of Premaitha explains to PharmaVentures’ Adrian Dawkes how this supports their strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha Health is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. With a higher detection rate and lower false positive rate than existing screening tests it gives pregnant women, their families and their doctors greater confidence in the result and reduces the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities. Steve Little, CEO of Premaitha explains to PharmaVentures’ Adrian Dawkes how this supports their strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Dr Steve Little
Stephen is a successful serial biotechnology entrepreneur. He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. DxS pioneered the use of molecular diagnostic tests such as KRAS and EGFR mutation analysis to predict the use of novel cancer therapies. In 2009, DxS was acquired by QIAGEN and Stephen became Vice President of Personalised Healthcare, responsible for developing companion diagnostic partnerships with the pharma industry. Prior to his leading role at DxS, Stephen worked for 20 years in various senior positions in the diagnostic divisions of Astra Zeneca and ICI. He holds a PhD from Heriot-Watt University in Edinburgh.
Premaitha Health
Premaitha Health (AIM: NIPT) is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their own facilities. This supports Premaitha’s strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere. Premaitha is listed on the AIM market of the London Stock Exchange. Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK.